Exchange: NASDAQ·Updated 07:47 PM EDT
GILD logo

GILDGilead Sciences, Inc.

$131.27
$5.30
(4.21%)
Today
Closed $131.27
$0.27
(0.21%)
After Hours
EarningsAug 6
Mkt Cap$162.98B
Vol8.09M
News
all
press releases
If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.07% on an annualized basis producing an average annual return of 11.3%. Currently, Gilead Sciences has a market capitalization ofread more...
Benzinga
News Placeholder
More News
News Placeholder
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Zacks
News Placeholder
KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug
KYMR surges 51% year to date as KT-621 advances in atopic dermatitis and asthma, with pivotal data timelines accelerating and pipeline momentum building.
Zacks
News Placeholder
Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?
Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
News Placeholder
Nurix Stock Up 29% in a Month: Here's What You Should Know
NRIX rallies on its collaboration with Roche for bexobrutideg, featuring a $700 million upfront payment and potential milestone payouts of up to $2.3 billion.
Zacks
News Placeholder
Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?
Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks
News Placeholder
Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $123.84, denoting a -1.05% move from the preceding trading day.
Zacks
News Placeholder
Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded Use
GILD wins FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer, opening a broader treatment opportunity.
Zacks
News Placeholder
U.S. FDA Approves Trodelvy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed antibody-drug conjugate (ADC), for the first-line treatment of adult patients with unresectable locally advanced...
Business Wire
News Placeholder
Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBC
Gilead secures EC approval to expand Trodelvy into first-line metastatic TNBC, marking a new treatment option and broadening its oncology reach.
Zacks
<
1
2
...
>

Advertisement|Remove ads.